| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6802301 | Journal of Substance Abuse Treatment | 2016 | 6 Pages |
Abstract
Nearly half of patients (47.7%) receiving office-based treatment with buprenorphine for their opioid use disorder had a positive hepatitis C virus antibody screening test although initiation of HCV treatment was nearly non-existent (2.21%).
Keywords
ETRHIPAAFIB-4PWIDALTEMRBoston Medical CenterDAAFDASVRBMCASTalanine transaminasepost-traumatic stress disorderPTSDRNAribonucleic acidpeople who inject drugsdirectly acting antiviralsbuprenorphineaspartate transaminaseOatHCV treatmentOpioid agonist therapyOpioid agonist treatmentICDFood and Drug AdministrationInternational Classification of DiseasesInfectious diseaseFibrosis-4electronic medical recordHepatitis C virusHCVhuman immunodeficiency virusHIVAntibodySustained virologic response
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Katelyn J. M.P.H., Wei M.P.H., Ph.D., Benjamin P. M.D., M.P.H., Judith I. M.D., M.P.H.,